Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval
Executive Summary
Amylin has agreed to a ban on direct-to-consumer advertising and other marketing restrictions for its diabetes therapy Symlin (pramlintide) as part of FDA's March 16 approval of the drug
You may also be interested in...
Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban
The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots
Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban
The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots
DTC Restrictions Ahead: Risk Management Plans, “Drug Watch” Are Vehicles
FDA will manifest its tougher stance on DTC advertising in requirements for more extensive risk management plans, Hogan & Hartson Partner Robert Brady predicted at a Regulatory Affairs Professionals Society conference in Chicago